FIRST NICE RECOMMENDED TARGETED TREATMENT OPTION FOR ELIGIBLE PATIENTS LIVING WITH UNRESECTABLE LOCALLY ADVANCED STAGE III EGFR-MUTATED LUNG CANCER

Contributed by: AstraZeneca

Tags

cancer

Oncology

More Like This

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

IMFINZI (DURVALUMAB) IN COMBINATION WITH CHEMOTHERAPY RECEIVES POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

PR Newswire associated0

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI